Drug Discov Today. 2003 Oct 1;8(19):876-7.

A 'rule of three' for fragment-based lead discovery?

Congreve M, Carr R, Murray C, Jhoti H.

Source

Astex Technology Ltd, 436 Cambridge Science Park, Milton Road, CB4 0QA, Cambridge, UK.

Comment on

Chris Lipinski discusses life and chemistry after the Rule of Five. [Drug Discov Today. 2003]
Chris Lipinski discusses life and chemistry after the Rule of Five.Lipinski CA. Drug Discov Today. 2003 Jan 1; 8(1):12-6.

PMID:: 14554012; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

Comment

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Medicines - MedlinePlus Health Information

Supplemental Content

Save items

Related citations in PubMed

Review Selective optimization of side activities: another way for drug discovery. [J Med Chem. 2004]
Review Selective optimization of side activities: another way for drug discovery.
Wermuth CG. J Med Chem. 2004 Mar 11; 47(6):1303-14.
Review Fragonomics: fragment-based drug discovery. [Curr Opin Chem Biol. 2005]
Review Fragonomics: fragment-based drug discovery.
Zartler ER, Shapiro MJ. Curr Opin Chem Biol. 2005 Aug; 9(4):366-70.
Institutional profile: Crystal structure information in drug discovery and development: current perspectives and new possibilities from the Cambridge Crystallographic Data Centre. [Future Med Chem. 2010]
Institutional profile: Crystal structure information in drug discovery and development: current perspectives and new possibilities from the Cambridge Crystallographic Data Centre.
Groom CR, Allen FH. Future Med Chem. 2010 Jun; 2(6):933-9.
Fragment-based lead discovery using X-ray crystallography. [J Med Chem. 2005]
Fragment-based lead discovery using X-ray crystallography.
Hartshorn MJ, Murray CW, Cleasby A, Frederickson M, Tickle IJ, Jhoti H. J Med Chem. 2005 Jan 27; 48(2):403-13.
Review Structural biology and drug discovery. [Curr Pharm Des. 2006]
Review Structural biology and drug discovery.
Scapin G. Curr Pharm Des. 2006; 12(17):2087-97.

See reviews... See all...

Cited by 29 PubMed Central articles

Comparative amino acid decomposition analysis of potent type I p38α inhibitors. [Daru. 2013]
Comparative amino acid decomposition analysis of potent type I p38α inhibitors.
Ebadi A, Razzaghi-Asl N, Khoshneviszadeh M, Miri R. Daru. 2013 May 29; 21(1):41. Epub 2013 May 29.
Virtual and Biophysical Screening Targeting the γ-Tubulin Complex - A New Target for the Inhibition of Microtubule Nucleation. [PLoS One. 2013]
Virtual and Biophysical Screening Targeting the γ-Tubulin Complex - A New Target for the Inhibition of Microtubule Nucleation.
Cala O, Remy MH, Guillet V, Merdes A, Mourey L, Milon A, Czaplicki G. PLoS One. 2013; 8(5):e63908. Epub 2013 May 15.
Ligand binding and aggregation of pathogenic SOD1. [Nat Commun. 2013]
Ligand binding and aggregation of pathogenic SOD1.
Wright GS, Antonyuk SV, Kershaw NM, Strange RW, Samar Hasnain S. Nat Commun. 2013; 4:1758.

See all...

Recent activity

Clear Turn Off Turn On

A 'rule of three' for fragment-based lead discovery?
A 'rule of three' for fragment-based lead discovery?
Drug Discov Today. 2003 Oct 1 ;8(19):876-7.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: